Scientific articles

 2017

  • Millet JP, Montalvo T, Bueno-Marí R, Romero-Tamarit A, Prats-Uribe A, Fernández L, Camprubí E, Del Baño L, Peracho V, Figuerola J, Sulleiro E, Martínez MJ, Caylà JA; Zika Working Group in Barcelona. Imported Zika Virus in a European City: How to Prevent Local Transmission? Front Microbiol. 2017 Jul 18;8:1319.
  • Altet N, Latorre I, Jiménez-Fuentes MÁ, Maldonado J, Molina I, González-Díaz Y, Milà C, García-García E, Muriel B, Villar-Hernández R, Laabei M, Gómez AC, Godoy P, de Souza-Galvão ML, Solano S, Jiménez-Ruiz CA, Domínguez J; PII Smoking SEPAR Working Group. Assessment of the influence of direct tobacco smoke on infection and active TB management. PLoS One. 2017 Aug 24;12(8):e0182998.
  • Maurino J, Molna-Pinargote I.V, Forcada N, Gónzalez-Diaz Y, Montes M, Ruiz M, Montoro M, Maldonado J, Soteras J, Altet N, Millet JP. Tuberculosis multirresistente y diabetes mellitus: la confluencia de dos pandemias genera casos complicados. Rev Enf Emerg 2017; 16(1): 36-39.
  • Altet N en representación del Grupo de Trabajo sobre TB y Diabetes Mellitus del TBNET. TB y Diabetes Mellitus, distribución en Europa. Estudio TBNet. Rev Enf Emerg 2017; 16(3): 172-173.
  • Martinez-Moragon E, Plaza V, Torres I, Rosado A, Urrutia I, Casas X, Hinojosa B, Blanco-Aparicio M, Delgado J, Quirce S, Sabadell C, Cebollero P, Muñoz-Fernández A. Fibromyalgia as a cause of uncontrolled asthma: a case-control multicenter study. Curr Med Res Opin. 2017 Dec;33(12):2181-2186.
  • Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 21;167(10):689-697.
  • González R, Camprubí E, Fernández L, Millet JP, Peracho V, Gorrindo P, Avellanés I, Romero A, Caylà JA. [Confirmed Dengue, Chikungunya and Zika Cases during the Period 2014 to 2016 in Barcelona, Spain]. Rev Esp Salud Publica. 2017 Mar 7;91. pii: e201701027. Spanish.
  • Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, Martinez JA, Kromann I, Penas A, Anibarro LL, de Souza-Galvão ML, Sánchez F, Rodrigo-Pendás JÁ, Noguera-Julian A, Martínez-Lacasa X, Tuñez MV, Fernández VL, Millet JP, Moreno A, Cobos N, Miró JM, Roldan L, Orcau A, Andersen P, Caylá JA; TESEC Working Group. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med. 2017 Apr;5(4):259-268.
  • Van Leth F, Günther G, Hoffmann H, Lange C; European MDR-TB Database Collaboration. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1489-1490.
  • Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet. Treatment outcomes of MDR-TB and HIV co-infection in Europe. Eur Respir J. 2017 Jun 8;49(6).
  • Bothamley GH, Lange Ch on behalf of TBNET (Altet N, Millet JP, et al.). Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trials group (TBNET) study. Respiratory Medicine2017; 132: 68-75.
  • Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C for the TBNET. Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion. Not Cure. Am J Respir Crit Care Med 2017; 196: 1222-1224.
  • Villar-Hernández R, Latorre I, Altet N, Dominguez J. Could IFN-γ levels in seral QuantiFERON predict tuberculosis development in young children?. J Lab Precision Medicine 2017; 2: 86.
  • Newsletter Red Tuberculosis y Solidaridad. Sección: Colaboradores de la Red. Serveis Clínics. 29 de Desembre de 2017.
  • Armstrong G, Millet JP, Caylà JA. Llibre: La visión de los pacientes sobre la tuberculosis a partir de sus fotografias. Patient Perspectives of the lived experience of tuberculosis through Photos. Ed: Esmon publicidad. Fundación de la Unidad de Investigación en Tuberculosis (FUITB).

2014

  • Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Lange C1, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D,Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW,Zellweger JP, Cirillo DM; for the TBNET. Eur Respir J. 2014 Mar 23. [Epub ahead of print]
  • Common errors in multidrug-resistant tuberculosis management. Monedero I, Caminero JA. Expert Rev Respir Med. 2014 Feb;8(1):15-23. doi: 10.1586/17476348.2014.856758. Epub 2013 Dec 16.

2013

  • Monitoring changes in antituberculosis treatment associated factors determined at the time of diagnosis. Altet MN, Vidal R, Milá, Rodrigo T, Casals M, Mir I, Ruiz-Manzano R, Jiménez-Fuentes MA, Sánchez F, Maldonado J, Blanquer R, de Souza Galvão ML, Solsona J, Azlor E, Diaz D, Calpe JL, Caylá JA. Int J Tuberc Lung Dis 2013; 17: 1435-1441.
  • Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Rodriguez M, Monedero I, Caminero JA, Encarnacion M, Dominguez Y, Acosta I, et al. Int J Tuberc Lung Dis. 2013 Apr;17(4):520-5.

2012

  • A predictive scoring instrument for tuberculosis lost to follow-up outcome. Rodrigo T, Caylá JA, Casals M, García-García JM, Caminero JÁ, Ruiz-Manzano J, Blanquer R, Vidal R, Altet N, Calpe JL, Penas A. and Working Group on Completion of Tuberculosis Treatment in Spain. Respiratory Research 2012; 13:75.
  • GenoType MTBDRs/ for Molecular Detection of Second-Line –Drug and Ethambutol Resistance in Mycobacetium tuberculosis Strains and Clinical Samples. J. Clin. Microbiol. 2012, 50(1):30 DOI: 10.1128/JCM.05274-11

2011

  • Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Trébucq A, Enarson D A, Chiang C Y, Van Deun A, Harries A D, Boillot F, Detjen A, Fujiwara P I, Graham S, Monedero I, Rusen I D, Rieder H L. Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72. doi: 10.5588/ijtld.11.0392
  • Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Monedero I, Caminero JA. Int J Tuberc Lung Dis. 2011 Apr;15(4):433-9
  • Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. García-Sierra N, Lacoma A, Prat C, Haba L, Maldonado J, Ruiz-Manzano J, Gavin P, Samper S, Ausina V, Domínguez J. J Clin Microbiol. 2011 Oct;49(10):3683-6. doi: 10.1128/JCM.01239-11. Epub 2011 Aug 3.

2010

  • On the way to shortening tuberculosis treatments: clinical trials of the Unitat d' Investagació en Tuberculosi de Barcelona supported by the Centers for Disease Control and Prevention. Moreno A, Sanchez F, Nelson J, Miró JM, Caylá JA and Grupo de Trabajo de la UITB-TBTC (site 31). Gac Sanit 2010; 24(2): 171.e1-6

2009

  • T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at thebeginning, during, and after antituberculosis treatment. Domínguez J, De Souza-Galvão M, Ruiz-Manzano J, Latorre I, Prat C, Lacoma A, Milà C, Jiménez MA, Blanco S, Maldonado J, Altet N, Ausina V. Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51. doi: 10.1016/j.diagmicrobio.2008.09.010. Epub 2008 Nov 21.

2008 y anteriores

  • Effectiveness and tolerance of antituberculosis treatment regimens without isoniazid and rifampicin: analysis of 85 cases. Tost JR, Vidal R, Maldonado J, Caylà JA. Arch Bronconeumol. 2008 Sep;44(9):478-83.
  • GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance inMycobacterium tuberculosis strains and clinical samples. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Rosés S, Maldonado J, Domínguez J. J Clin Microbiol. 2008 Nov;46(11):3660-7. doi: 10.1128/JCM.00618-08. Epub 2008 Sep 10.
  • Multirresistencias. Enf. Emergentes. S, Maldonado. 2007, 9,168-169.
  • Tractament directament observat en TBC. Estratègies per millorar l´adherència al tratctamenti importancia de la col-laboració amb agents de salud i terballadores socials. Annals de Medicina. 2006; 89, 1: 21-23
  • Experiencia en inmigrantes en Serveis Clínics de Barcelona. Enf. Emergentes. 2005, 7,179-181.
  • Documento de consenso sobre la prevención y el control de las tuberculosis importadas. Grupo de trabajo de los talleres de 2001 y 2002 de la Unidad de Investigación en Tuberculosis de Barcelona .UITB.  Med. Clin (Barc) 2003; 121(14):549-62.
  • Características diferenciales de la TBC en inmigrantes. Visión de un Centro de tratamiento directamente observado. J. Maldonado,  (TDO). Enf. Emerg. 2002; 4(4): 194-196.
  • Resultados e impacto epidemiológico de una Unidad de Tratamiento Directamente Observado de la Tuberculosis. J. Alcaide, J. Pascual, M.N. Altet, J. Maldonado, F. López Espinosa, Ll. Sayeras. Arch. Bronconeumolog. 1999. 35: 267
  • Patogénesis e Inmunidad de la Tuberculosis. Diagnóstico de la Tuberculosis. Radiología. Medicina Integral. J. Maldonado Díaz de Losada. Tema Monográfico. 23: 1994.
  • Protocols per a la prevenció i el control de la tuberculosi en l´atenció primaria de salud. Barcelona. Departament de Sanitat i Seguritat Social. Generalitat de Cataluña. 1994.

 

 

 

DOOTT (ETODA)

Directly Observed Outpatient Therapy Team.

DOOTT Team manages the administration for outpatient’s medication, always supervised by our medical staff. DOOTT is an entity that works as a branch of Serveis Clínics, integrated to the Catalonia’s Healthcare network (CatSalut).

Direct Contact with Serveis Clínics

Address: Carrer García Mariño 4 · 08022 - Barcelona

This email address is being protected from spambots. You need JavaScript enabled to view it. // This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +34 93 417 46 01 // +34 93 417 46 02

Fax: +34 93 418 91 72